Cytology is the study of cells using a microscope.
Cervical cancer is often thought of as a disease that primarily affects young women. Because of this, many older women fail to keep up with appropriate screening as they age.
To support healthcare and scientific research groups with high quality cytological cell samples, the National Clinical Cytology Biobank at the Karolinska Institute in Stockholm (Sweden) has invested in 2D coded sample storage tubes and sample handling equipment from Micronic to provide traceable, high integrity storage of its valuable gynaecological cell samples.
Pancreatic cancer has the lowest survival rate among all major cancers, largely because physicians lack diagnostic tools to detect the disease in its early, treatable stages.
Zilico Ltd – a developer of a pioneering cervical cancer diagnostic system - has been selected by the IFC, a member of the World Bank Group, to be part of a unique program across India.
After years of trying, biologists have succeeded in creating an extremely bright red fluorescent protein in the lab.
A pioneering diagnostic system that is having a significant impact on the changing clinical pathway for cervical cancer will be on display at MEDICA 2016 by multi-award winning company, Zilico Ltd.
The American Society of Clinical Oncology today issued a new global guideline on screening for cervical cancer, one of the leading causes of cancer related death among women worldwide.
Veracyte, Inc.today announced new data suggesting the potential to enhance the performance of the Afirma Gene Expression Classifier in thyroid cancer diagnosis by combining the test's proven RNA expression-based capabilities with gene variant and fusion information – all on a single, robust RNA sequencing platform.
Olympus announces the launch of its new Microscopy web store, a full-featured e-commerce platform that makes it simple for customers to find the products they want.
Interpace Diagnostics Group, a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management, reported today that the Company has launched a new version of their AccuCEA™ product called "Insights" for Gastroenterologists who focus on diagnosing and treating pancreatic cancer.
Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations.
The U.S. Food and Drug Administration today approved the Roche cobas HPV Test as the first test for Human Papilloma Virus (HPV) that can be used with cervical cells obtained for a Pap test and collected in SurePath Preservative Fluid.
QIAGEN N.V. today announced the launch of the QIAsure Methylation Test, a novel CE-marked molecular diagnostic test for use in differentiating patients' risk of developing cervical cancer.
Cytopathology researchers at Houston Methodist Hospital recently found that combining two diagnostic tests, Pap and high-risk human papillomavirus (hrHPV), dramatically decreased the chance of missing tumors and high-grade lesions by sevenfold.
If a patient is ill and takes drugs for that illness, these drugs often lead to further illnesses and complications. This affects millions of people throughout the world.
Researchers at Women & Infants Hospital, a Care New England hospital, recently published the results of a study demonstrating a connection between anal cancer and human papillomavirus (HPV) infection.
A group of neurobiologists from Russia and the USA, including Dmitry Smagin, Tatyana Michurina, and Grigori Enikolopov from Moscow Institute of Physics and Technology, have proven experimentally that aggression has an influence on the production of new nerve cells in the brain.
Interpace Diagnostics announced today that Laboratory Corporation of America Holdings, the world's leading health care diagnostics company, will begin offering Interpace's new ThyraMir microRNA classifier test.
Lung cancer is the leading cause of cancer mortality in the United States, with a five-year survival rate of just 17 percent. Smoking causes approximately 85 percent of all lung cancer cases, only 15 percent of which are diagnosed at an early stage. Most efforts to obtain early diagnosis have been unsuccessful, largely due to the highly aggressive nature of the disease.
DP Medical Systems Ltd has secured a deal with Central Manchester University Hospitals NHS Foundation Trust (CMFT) to adopt ZedScan™ as part of its cervical cancer care pathway.